PRCT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRCT

Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"), of the important September 22, 2026 lead plaintiff deadline.

If you purchased PROCEPT common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

To join the PROCEPT class action, go to https://rosenlegal.com/cases/procept-biorobotics-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2026.

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

According to the lawsuit, throughout the Class Period, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) during the Class Period, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (2) Procept's undisclosed discount program had artificially and unsustainably inflated Procept's reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (3) Procept's undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (4) Procept's consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept's customer base, amounting to more than 10,000 excess units by the end of the Class Period; (5) as a result of the foregoing, defendants' representations during the Class Period regarding Procept's handpiece unit sales and the utilization of Procept's field Systems were materially overstated; and (6) as a result of the foregoing, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (7) as a result of the foregoing, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.

When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the PROCEPT class action, go to https://rosenlegal.com/cases/procept-biorobotics-corporation/join or call Phi...